Raoul Herbrecht
Herbrecht, Raoul
VIAF ID: 51864648 (Personal)
Permalink: http://viaf.org/viaf/51864648
Preferred Forms
- 200 _ | ‡a Herbrecht ‡b Raoul
- 100 1 _ ‡a Herbrecht, Raoul
- 100 1 _ ‡a Herbrecht, Raoul
- 100 0 _ ‡a Raoul Herbrecht
4xx's: Alternate Name Forms (5)
5xx's: Related Names (2)
- 511 2 _ ‡a Interface de recherche fondamentale et appliquée en cancérologie (Strasbourg)
- 511 2 _ ‡a Université de Strasbourg (2009-....)
Works
Title | Sources |
---|---|
Amphotericine B en dispersion colloïdale : évaluation de l'efficacité et de la tolérance : à propos de 5 études de phase I-II chez 572 patients : (DES MEDECINE INTERNE) | |
Autoimmune phenomena pathogenesis in chronic lymphocytic leukemia : the role of ZAP-70. | |
Cancers cutanés et traitement prolongé par voriconazole : à propos de deux cas et revue de la littérature | |
EFFETS DU RHUG-CSF ET DU RHUM-CSF DANS UN MODELE DE CANDIDOSE EXPERIMENTALE MURINE | |
Evolution des stratégies thérapeutiques des aspergilloses invasives : Etude d'une cohorte de 544 patients | |
Hémophagocytose lymphohistiocytaire et infection fongique invasive : Étude retrospective monocentrique : Thèse présentée pour le diplôme d'État de docteur en médecine, Diplôme d'État, Mention D. E. S. Médecine interne et immunologie clinique | |
HISTIOCYTIC SARCOMA, A DISEASE OF DIFFICULT DIAGNOSING AND TREATING . | |
Identification de biomarqueurs de réponse à l'azacitidine dans les leucémies aigues myéloïdes du sujet âgé | |
Identification d'un nouveau facteur de risque de retard d' élimination et d'intoxication au méthotrexate : les inhibiteurs de la pompe à protons | |
Identification of biomarkers of response to azacitidine in older patients with acute myeloid leukemia. | |
Infections en hématologie | |
Infections fongiques compliquant les hémopathies et les greffes de cellules souches : incidence, facteurs de risque, mortalité, et développement de scores prédictifs décisionnels pour améliorer la pertinence des prophylaxies | |
Infections fongiques invasives : épidémiologie et optimisation thérapeutique | |
Les infections invasives à champignons filamenteux dans les hémopathies lymphoïdes : étude rétrospective de 348 cas | |
Interactions médicamenteuses des antifongiques azolés systémiques | |
Invasive fungal diseases : epidemiology and treatment optimization. | |
Invasive mold diseases in patients with a lymphoproliferative disease: a retrospective analysis on 348 patients. | |
Invasive mold infections in lung transplantation : a 10 years retrospective monocentric study. | |
Invasive mucormycosis : a study of 57 cases in a tertiary care hospital in Strasbourg between 1995 and 2015. | |
Longer-term follow-up and outcome by tumour cell proliferation rate | |
Les lymphomes malins primitifs du sein | |
Maladies du sang et transfusion : module 17 : DCEM 3, 2006-2007 | |
Managing the challenges of invasive fungal infections | |
Mécanismes physiopathologiques des manifestations auto-immunes au cours de la leucémie lymphoïde chronique : rôle de ZAP-70 | |
Mucormycoses invasives : étude rétrospective de 57 cas aux Hôpitaux universitaires de Strasbourg de 1955 à 2015 | |
Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French Multicentre Cohort Study (2003-2008) | |
Multimodality Diagnosis Approach of Cardiac Aspergillosis | |
Myélodysplasie et leucémies aiguës secondaires après cancer du sein : implication des mutations de BRCA1/2 | |
New pharmacological opportunities for the treatment of invasive mould diseases. | |
Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma | |
Place du séquençage haut débit dans la prise des patients en rechute d'une leucémie aiguë myéloïde | |
Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. | |
Posaconazole as Salvage Treatment for Invasive Fusariosis in Patients with Underlying Hematologic Malignancy and Other Conditions | |
[Potential clinical impact of therapeutic education in patients treated with anticancer drugs] | |
Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts | |
Prise en charge des extravasations de cytotoxiques anticancéreux | |
Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs | |
Prognostic factors in ovarian carcinoma in complete histologic remission at second-look surgery | |
Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials | |
Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis | |
Prospective study of bacteraemia in cancer patients | |
Proteomic analysis of malignant lymphocyte membrane microparticles using double ionization coverage optimization | |
Le purpura thrombotique thrombocytopénique aux Hôpitaux Universitaires de Strasbourg de 1998 à 2008 : aspects cliniques, biologiques et thérapeutiques. | |
Real-world non-interventional long-term post-authorisation safety study of ruxolitinib in myelofibrosis | |
Relations entre profils microbiologiques de l'environnement intérieur et maladies respiratoires infectieuses et allergiques | |
Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients | |
Risk factors and mortality in invasive Rasamsonia spp. infection: Analysis of cases in the FungiScope® registry and from the literature | |
Risk stratification for invasive aspergillosis in immunocompromised patients. | |
Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. | |
Saccharomyces cerevisiae fungemia: an adverse effect of Saccharomyces boulardii probiotic administration | |
Safety and efficacy of Intralipid emulsions of amphotericin B | |
Le sarcome histiocytaire, une entité de diagnostic et de traitement difficile | |
Secondary myelodysplasia and acute leukemia after breast cancer : involvement of BRCA1/2 mutations. | |
Severe methotrexate toxicity due to a concomitant administration of ciprofloxacin | |
Severe Neutropenia and Agranulocytosis Related to Antithyroid Drugs: A Study of 30 Cases Managed in A Single Reference Center | |
Stimulation of B-cell lymphoproliferations with CpG-oligonucleotide DSP30 plus IL-2 is more effective than with TPA to detect clonal abnormalities | |
Successful outcome of treatment of a disseminated infection due to Fusarium dimerum in a leukemia patient | |
Successful treatment of a granulocytic sarcoma of the uterine cervix in complete remission at six-year follow-up. | |
Successful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung transplant recipient | |
Successful treatment of visceral leishmaniasis with high-dose amphotericin B diluted in fat emulsion: a case report | |
Suivi épidémiologique des aspergilloses invasives en oncohématologie pendant une période de travaux | |
Systematic review and mixed treatment comparison of randomized evidence for empirical, pre-emptive and directed treatment strategies for invasive mould disease | |
Systematic review and network meta-analysis of clinical outcomes associated with isavuconazole versus relevant comparators for patients with invasive aspergillosis | |
Systemic Antifungal Prophylaxis in Patients Hospitalized in Hematology Units in France: The AFHEM Cross-Sectional Observational Study | |
Towards novel paradigms for cancer therapy. | |
TRAITEMENT DES INFECTIONS FONGIQUES SYSTEMIQUES : DE L'AMPHOTERICINE B CONVENTIONNELLE AUX NOUVELLES FORMES LIPIDIQUES | |
Traitement par l'association pipéracilline et nétilmicine des infections chez les patients agranulocytaires | |
Transcriptomic approach contribution in the physiopathology and treatment of hematological malignancies. | |
A translocation t(2;8)(q12;p11) fuses FGFR1 to a novel partner gene, RANBP2/NUP358, in a myeloproliferative/myelodysplastic neoplasm | |
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America | |
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial | |
Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients | |
Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera | |
Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment | |
A unique proteomic profile on surface IgM ligation in unmutated chronic lymphocytic leukemia | |
Validation by real-life data of the new radiological criteria of the revised and updated consensus definition for invasive fungal diseases | |
Ventricular bigeminy associated with voriconazole, methadone and esomeprazole | |
Voriconazole: therapeutic review of a new azole antifungal | |
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis | |
VP-16, ifosfamide, and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen | |
Waldenström's macroglobulinemia harbors a unique proteome where Ku70 is severely underexpressed as compared with other B-lymphoproliferative disorders |